TEAM
Over 100 years of experience
BHCRG WAS FORMED IN 2012
It is led by the investigators who made the initial discoveries that led to this new family of drugs. Our team has expertise in diverse areas including chemical carcinogenesis and mutagenesis, molecular biology and pathology, animal drug testing, cellular stress response biology, and toxicology.
Owner and CEO
DALE M. WALKER, DVM
Dale M. Walker has 32 years of experience. She has particular expertise in cellular stress response pathways and their outcomes in mammalian cells, and was instrumental in the development of the “Stress Response Resolution Assay” (SRRR assay). Knowledge obtained from the development of this assay was critical to the discovery and development of the BRG family of drugs.
CSO
VERNON E. WALKER, DVM, PHD
Vernon has 35 years experience in the fields of chemical carcinogenesis and mutagenesis, molecular biology, pathology and toxicology. He and Dale were instrumental in the discoveries of the broad spectrum antiviral activity of the aminothiol compound called WR1065, and in the discoveries that led to the development of the BRG family of drugs.
DR. MIRIAN POIRER, PHD
Dr. Miriam Poirier, a proposed advisor, is the past head of the Carcinogen-DNA Interactions Section at the NCI and a long-term collaborator who investigated therapeutic activities of WR1065. She continues to provide ongoing advise and support for the advancement of the BRG drug family.